Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2005 Sep 27;10239:13767-72. doi: 10.1073/pnas.0504613102.
Show Gene links
Show Anatomy links
Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII.
Clark RJ
,
Fischer H
,
Dempster L
,
Daly NL
,
Rosengren KJ
,
Nevin ST
,
Meunier FA
,
Adams DJ
,
Craik DJ
.
???displayArticle.abstract???
Conotoxins (CTXs), with their exquisite specificity and potency, have recently created much excitement as drug leads. However, like most peptides, their beneficial activities may potentially be undermined by susceptibility to proteolysis in vivo. By cyclizing the alpha-CTX MII by using a range of linkers, we have engineered peptides that preserve their full activity but have greatly improved resistance to proteolytic degradation. The cyclic MII analogue containing a seven-residue linker joining the N and C termini was as active and selective as the native peptide for native and recombinant neuronal nicotinic acetylcholine receptor subtypes present in bovine chromaffin cells and expressed in Xenopus oocytes, respectively. Furthermore, its resistance to proteolysis against a specific protease and in human plasma was significantly improved. More generally, to our knowledge, this report is the first on the cyclization of disulfide-rich toxins. Cyclization strategies represent an approach for stabilizing bioactive peptides while keeping their full potencies and should boost applications of peptide-based drugs in human medicine.
Adessi,
Converting a peptide into a drug: strategies to improve stability and bioavailability.
2002, Pubmed
Adessi,
Converting a peptide into a drug: strategies to improve stability and bioavailability.
2002,
Pubmed
Berman,
The Protein Data Bank.
2000,
Pubmed
Brünger,
New applications of simulated annealing in X-ray crystallography and solution NMR.
1997,
Pubmed
Cartier,
A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors.
1996,
Pubmed
,
Xenbase
Chakshusmathi,
Native-state hydrogen-exchange studies of a fragment complex can provide structural information about the isolated fragments.
1999,
Pubmed
Chiche,
Squash inhibitors: from structural motifs to macrocyclic knottins.
2004,
Pubmed
Craik,
Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif.
1999,
Pubmed
Cudic,
Development of novel antibacterial peptides that kill resistant isolates.
2002,
Pubmed
Dawson,
Synthesis of proteins by native chemical ligation.
1994,
Pubmed
Deechongkit,
The effect of backbone cyclization on the thermodynamics of beta-sheet unfolding: stability optimization of the PIN WW domain.
2002,
Pubmed
Dutton,
alpha-Conotoxins: nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads.
2001,
Pubmed
Everhart,
Determinants of potency on alpha-conotoxin MII, a peptide antagonist of neuronal nicotinic receptors.
2004,
Pubmed
,
Xenbase
Güntert,
Torsion angle dynamics for NMR structure calculation with the new program DYANA.
1997,
Pubmed
Harvey,
Determinants of specificity for alpha-conotoxin MII on alpha3beta2 neuronal nicotinic receptors.
1997,
Pubmed
,
Xenbase
Hill,
Three-dimensional solution structure of alpha-conotoxin MII by NMR spectroscopy: effects of solution environment on helicity.
1998,
Pubmed
Hogg,
Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor.
1999,
Pubmed
Hogg,
Alpha-conotoxins PnIA and [A10L]PnIA stabilize different states of the alpha7-L247T nicotinic acetylcholine receptor.
2003,
Pubmed
,
Xenbase
Hubbard,
The structural aspects of limited proteolysis of native proteins.
1998,
Pubmed
Hutchinson,
PROMOTIF--a program to identify and analyze structural motifs in proteins.
1996,
Pubmed
Laskowski,
AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR.
1996,
Pubmed
Lawrence,
Botulinum A and the light chain of tetanus toxins inhibit distinct stages of Mg.ATP-dependent catecholamine exocytosis from permeabilised chromaffin cells.
1994,
Pubmed
Livett,
Drugs from the sea: conopeptides as potential therapeutics.
2004,
Pubmed
Miljanich,
Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
2004,
Pubmed
Powell,
Peptide stability in drug development: a comparison of peptide reactivity in different biological media.
1992,
Pubmed
Powell,
Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum.
1993,
Pubmed
Quik,
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
2001,
Pubmed
Rosengren,
Twists, knots, and rings in proteins. Structural definition of the cyclotide framework.
2003,
Pubmed
Schnölzer,
In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences.
1992,
Pubmed
Shon,
Three-dimensional solution structure of alpha-conotoxin MII, an alpha3beta2 neuronal nicotinic acetylcholine receptor-targeted ligand.
1997,
Pubmed
Tachikawa,
Characterization of the functional subunit combination of nicotinic acetylcholine receptors in bovine adrenal chromaffin cells.
2001,
Pubmed
,
Xenbase
Terlau,
Conus venoms: a rich source of novel ion channel-targeted peptides.
2004,
Pubmed
Wishart,
1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects.
1995,
Pubmed
